Nanotechnology Now - Press Release: FAU researchers develop nanoparticles for biomedical applications

Home > Press > FAU researchers develop nanoparticles for biomedical applications

Image: Panthermedia/Andriy Popov

Abstract:
An international, interdisciplinary team of researchers is developing highly porous biomaterials for localised release of therapeutic ions and drugs in the MOZART project which has received 4.65 million euros in funding. Materials scientist Prof. Dr. Aldo R. Boccaccini is head of the team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), one of the project’s academic partners. MOZART is being funded by Horizon 2020, the EU Framework Programme for Research and Innovation.

FAU researchers develop nanoparticles for biomedical applications

Erlangen, Germany | Posted on January 19th, 2016

The body’s powers of regeneration sometimes fail. Around 350,000 people a year suffer from broken bones that cannot heal by themselves, while around 2.2 million patients with conditions such as diabetes have to cope with chronic open wounds. MOZART (Mesoporous matrices for localized pH-triggered release of therapeutic ions and drugs) aims to help these patients. The goal of the project is to use mesoporous – i.e. highly porous – silicate nanomaterials to support bone and wound healing.
The team of FAU researchers led by Prof. Dr. Aldo R. Boccaccini, Chair of Biomaterials, are developing new inorganic and mesoporous materials whose pores are approximately ten nanometres in size and which have a unique chemical composition. ‘The pores of these bioactive particles will be enriched with active agents and are designed to release medication locally in a controlled manner, meaning that the active agent is released in the location where it is required,’ Prof. Boccaccini explains. ‘This allows doses to be reduced and side affects to be avoided.’
The overall goal of the four-year project is to develop a database of new and bioactive nanomatrices. ‘We are delighted that we are able to contribute our expertise to such an important project,’ Prof. Boccaccini says. ‘If our new and innovative developments can be used in clinical application, this will benefit patients and enrich Europe’s healthcare sector.’
The MOZART consortium consists of five high-tech SMEs and six European universities, including FAU, the Polytechnic University of Turin, Complutense University of Madrid and the University of Sheffield. The European Commission is funding the project with a total of 4.65 million euros. As an academic partner, FAU’s Institute for Biomaterials has been allocated around 382,000 euros of this funding.

####

For more information, please click here

Contacts:
Prof. Dr Aldo R. Boccaccini
Phone: +49 9131 8528601
aldo.boccaccini@ww.uni-erlangen.de

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: